Clinical Trial Update: Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial. [Phase 3]

View source ↗

Summary

This clinical trial update outlines the Phase III REINFORCE trial evaluating intensification with docetaxel plus apalutamide in metastatic hormone-sensitive pro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer
• Prostate Cancer

Drugs mentioned

• ERLEADA (apalutamide)
• Taxotere (docetaxel)

Snippet

Sponsor: Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD | Conditions: Metastatic Hormone-sensitive Prostate Cancer | Phase 3 | Status: NOT_YET_RECRUITING